LOGIN  |  REGISTER
C4 Therapeutics
C4 Therapeutics

Agilent Technologies to Announce Third-Quarter Fiscal Year 2023 Financial Results Aug. 15

July 19, 2023 | Last Trade: US$107.17 28.93 -21.26

SANTA CLARA, Calif. / Jul 19, 2023 / Business Wire / Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2023 after the stock market closes on Tuesday, Aug. 15. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT.

To join the listen-only conference call webcast, click the link on the Events section of Agilent’s investor relations website. A recording of the call will also be available on the website for 90 days.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insight and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Astria Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page